AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer

AstraZeneca Begins a New Global Study of FASLODEX® (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer PR Newswire LONDON, October 29, 2012 LONDON, October 29, 2012 /PRNewswire/ -- FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial to ®compare fulvestrant to anastrozole (ARIMIDEX ) tablets in hormonal therapy-naïve, postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer. AstraZeneca today announced the start of a Phase III registration study (FALCON), a global clinical trial involving 450 postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population. Fulvestrant 500 mg is currently indicated for the treatment of postmenopausal women with oestrogen receptor-positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or [1]disease progression on therapy with an anti-oestrogen.